Deferasirox does not induce QT/QTc-prolongation in healthy subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 5, 2009, Pages 321-327

  Sechaud, Romain ^a   Dumortier, T ^a   Balez, S ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS PHARMA K K   (Japan)

Author keywords

Cardiac repolarization; Deferasirox; Exjade; Iron chelator; QT QTc interval

Indexed keywords

DEFERASIROX; MOXIFLOXACIN; PLACEBO; BENZOIC ACID DERIVATIVE; HETEROCYCLIC COMPOUND; IRON CHELATING AGENT; QUINOLINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; HEART REPOLARIZATION; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; LOOSE FECES; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PR INTERVAL; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; TACHYCARDIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN; ADOLESCENT; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAPHY; LONG QT SYNDROME; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; AZA COMPOUNDS; BENZOIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; IRON CHELATING AGENTS; LONG QT SYNDROME; MALE; MIDDLE AGED; QUINOLINES; TRIAZOLES; YOUNG ADULT;

EID: 67649394458     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP47321     Document Type: Article

References (20)

1. Bloomfield D, Krishna R. Commentary on the clinical relevance of concentration/QTc relationships for new drug candidates. J Clin Pharmacol. 2008; 48: 6-8.
2. Darpo B, Nebout T, Sager PT. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline. J Clin Pharmacol. 2006; 46: 498-507.
3. Demolis JL, Kubitza D, Tenneze L, Funck-Brentano C. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther. 2000; 68: 658-666.
4. European Medicines Agency. Scientific discussion on Exjade (2006). Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/exjade/ H-670-en6.pdf; accessed October 21, 2008.
5. Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia. J Clin Pharmacol. 2003; 43: 565-572.
6. Galanello R, Piga A, Cappellini MD, Forni GL, Zappu A, Origa R, Dutreix C, Belleli R, Ford JM, RiviPre GJ, Balez S, Alberti D, Sechaud R. Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen. J Clin Pharmacol. 2008; 48: 428-435.
7. Hulhoven R, Rosillon D, Letiexhe M, Meeus MA, Daoust A, Stockis A. Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. Eur J Clin Pharmacol. 2007; 63: 1011-1017.
8. ICH E14 draft guideline. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. (draft ICH consensus guideline). June 10, 2004. Available from URL: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/ ich/consultation/e14_step2_esape2_e.html; accessed July 29; 2008.
9. ICH E14 guidance. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Federal Register. 2005; 70: 61134-61135.
10. Lettieri J, Vargas R, Agarwal V, Liu P. Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400 mg in healthy male volunteers. Clin Pharmacokinet. 2001; 40 (Suppl 1): 19-25.
11. Lindsey WT, Olin BR. Deferasirox for transfusion-related iron overload: a clinical review. Clin Ther. 2007; 29: 2154-2166.
12. Nick H, Wong A, Acklin P, Faller B, Jin Y, Lattmann R, Sergejew T, Hauffe S, Thomas H, Schnebli HP. ICL670A: preclinical profile. Adv Exp Med Biol. 2002; 509: 185-203.
13. Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, Donato G, Bordone E, Lavagetto A, Zanaboni L, Sechaud R, Hewson N, Ford JM, Opitz H, Alberti D. Randomized Phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006; 91: 873-880.
14. Porter JB. Deferasirox: an effective once-daily orally active iron chelator. Drugs Today. 2006; 42: 623-637.
15. Sechaud R, Dutreix C, Balez S, Pommier F, Dumortier T, Morisson S, Brun E. Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks. Int J Clin Pharmacol Ther. 2008a; 46: 102-108.
16. Sechaud R, Robeva A, Belleli R, Balez S. Absolute oral bioavailability and disposition of deferasirox in healthy human subjects. J Clin Pharmacol. 2008b; 48: 919-925.
17. Serra DB, Affrime MB, Bedigian MP, Greig G, Milosavljev S, Skerjanec A, Wang Y. QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol. 2005; 45: 1038-1047.
18. Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother. 1999; 43 (Suppl. B): 83-90.
19. VanOrden HE, Hagemann TM. Deferasirox - an oral agent for chronic iron overload. Ann Pharmacother. 2006; 40: 1110-1117.
20. Yang LP, Keam SJ, Keating GM. Deferasirox: a review of its use in the managementof transfusional chronic iron overload. Drugs. 2007; 67: 2211-2230.